Case report: A de novo ERBB3 mutation develops in a gallbladder cancer patient carrying BRCA1 mutation after effective treatment with olaparib

Case report: A de novo ERBB3 mutation develops in a gallbladder cancer patient carrying BRCA1 mutation after effective treatment with olaparib

BackgroundGallbladder cancer (GBC) is highly lethal and resistant to most chemotherapeutic drugs. GBC was reported to carry multiple genetic mutations such as TP53, K-RAS, and ERBB2/3. Here, we unexpectedly identified a patient with GBC harboring germline BRCA1 p.Arg1325Lys heterozygous mutation. We...

Full description

Bibliographic Details
Main Authors: Jing-Xiao Yang, Zi-Yao Jia, Fa-Tao Liu, Wen-Guang Wu, Xue-Chuan Li, Lu Zou, Huai-Feng Li, Fei Zhang, Run-Fa Bao, Shu-You Peng, Wan Yee Lau, Yun Liu, Mao-Lan Li, Ying-Bin Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Oncology
Subjects:
gallbladder cancer
dual targeted drugs therapy
olaparib
drug resistance
conversion therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1078388/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1078388/full

Similar Items